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OBJECTIVE — To ascertain whether simple indexes of insulin sensitivity based on a fasting
blood sample may be reliable measures of insulin sensitivity in combined kidney-pancreas–
transplanted patients.
RESEARCH DESIGN AND METHODS — Estimates of insulin sensitivity based on
fasting plasma glucose, insulin (homeostasis model assessment of insulin sensitivity [HOMA-IS],
Quantitative Insulin Sensitivity Check Index [QUICKI]), and free fatty acid (revised QUICKI)
concentrations were compared with insulin sensitivity as assessed with the gold standard tech-
nique (euglycemic-hyperinsulinemic clamp) in 22 patients who had undergone kidney-pancreas
transplantation (KP-Tx) and 18 matched healthy subjects (NOR).
RESULTS — In KP-Tx patients, indexes based on the glucose-insulin product, HOMA-IS (r
0.47, P 0.03) and QUICKI (r 0.47, P 0.03), were shown to be reliable measures of insulin
sensitivity. The introduction of fasting plasma free fatty acid concentration in the revised
QUICKI (r  0.76, P  0.0001) considerably improved the power of prediction of the clamp-
based measure of insulin sensitivity as observed in the healthy control subjects (r  0.83, P 
0.0001).
CONCLUSIONS — This study shows that in KP-Tx patients, HOMA-IS and QUICKI are
reliable measures of insulin sensitivity; the additional incorporation of fasting plasma free fatty
acid concentration into the glucose-insulin product (revised QUICKI) resulted in a considerably
more powerful index.
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The most effective established treat-ment for patients with type 1 diabe-tes and kidney failure is achieved
with combined kidney-pancreas trans-
plantation (KP-Tx). As of July 2000,
14,000 pancreas transplantations had
been reported to the International Pan-
creas Transplant Registry (IPTR). During
the last years, improvements in the surgi-
cal techniques and in the immunosup-
pressive drug regimens determined a
significant increase in patients and graft
survival after transplantation as well as
freedom from exogenous insulin admin-
istration in80% of cases at 1 year post-
transplantation in most centers (1).
Hyperinsulinemia and peripheral
insulin resistance caused by systemic
insulin delivery, prednisone therapy
(2– 4), and organ denervation (5) were
recognized consequences of pancreas
transplantation. Insulin resistance, pre-
sumably induced by steroid therapy, was
also found to be a possible cause of acute
deterioration of pancreatic graft function
(6). The recognition of insulin resistance,
therefore, has investigational and clinical
relevance in KP-Tx patients.
The insulin clamp technique (7) is
considered the “gold standard” (8) for in
vivo quantification of insulin sensitivity;
however, the method is complex and ex-
pensive. A well-accepted alternative is the
minimal model analysis of a frequently
sampled intravenous glucose tolerance
test (9), which is less laborious but is not
as simple as required in large-scale stud-
ies. Homeostasis model assessment of
insulin sensitivity (HOMA-IS) was pro-
posed as a simple and inexpensive tool
and is based on the product of the fasting
plasma insulin and blood glucose concen-
trations, measured in a single blood sam-
ple, divided by a constant (10). HOMA-IS
was shown to be a reliable surrogate
measure of in vivo insulin sensitivity in
humans when compared with the eugly-
cemic-hyperinsulinemic clamp technique
in individuals with various degrees of glu-
cose tolerance and insulin sensitivity (11).
Lately, it was proposed that because the
distribution of fasting insulin values is
skewed, transforming data taking both
the logarithm and the reciprocal of the
insulin-glucose product might be advan-
tageous; in fact, a better prediction of in-
sulin sensitivity was obtained (12) and the
new index has been called the Quantita-
tive Insulin Sensitivity Check Index
(QUICKI). Recently, our group showed
that the introduction of the logarithm and
the reciprocal of plasma free fatty acid
(FFA) concentration to the insulin-
glucose product was advantageous in
nondiabetic individuals with moderate al-
terations of insulin sensitivity (13). The
above-described indexes have been
shown to predict insulin sensitivity in
conditions classically characterized by in-
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sulin resistance (type 2 diabetes, obesity)
(14), and this study was undertaken to
test whether these indexes may be used as
predictors of whole-body insulin sensitiv-
ity in KP-Tx patients.
RESEARCH DESIGN AND
METHODS
Subjects
A total of 22 recipients of KP-Tx were
studied in the Istituto Scientifico H San
Raffaele. Patients received a segmental
(n  7) or whole-organ (n  15) trans-
plantation with anastomosis of the duo-
denal segment to the bladder for drainage
of exocrine secretions and with systemic
venous anastomosis to the iliac vein. Five
of these patients needed replacement of
insulin via subcutaneous administration
to achieve optimal control of glucose ho-
meostasis at the time the study was per-
formed. All patients were in stable clinical
and nutritional conditions. A total of 18
healthy subjects matched for anthropo-
metric features served as the control
group. Clinical and laboratory character-
istics of the study groups are summarized
in Table 1. Subjects were fully informed of
the possible risk of the study and gave
their consent. The protocol was approved
by the Ethical Committee of the Istituto
Scientifico H San Raffaele.
Experimental protocol
Subjects were instructed to consume an
isocaloric diet and to abstain from exer-
cise activity for 3 weeks before the study.
Transplanted patients were treated with
prednisone, cyclosporine, and azathio-
prine. Subjects took medications accord-
ing to the schedule except for prednisone,
which was held until completion of the
study. Use of other drugs with potential
effects on glucose and insulin metabolism
was discontinued for a washout period of
1 day. Patients receiving subcutaneous in-
sulin were instructed to take the last doses
of intermediate and short-acting insulin
24 and 12 h, respectively, before the eu-
glycemic-hyperinsulinemic clamp, which
was performed to assess insulin sensitivity
after a 10-h overnight fast.
Euglycemic-hyperinsulinemic clamp.
Subjects were admitted to the Metabolic
Unit of the Division of Internal Medicine I
of the Istituto Scientifico H San Raffaele at
7:00 A.M. after a 10-h overnight fast. A
Teflon catheter was inserted into an ante-
cubital vein for infusion and an additional
catheter was inserted retrogradely into a
wrist vein for blood sampling. The hand
was kept in a heated box (50°C) through-
out the experiment to allow sampling of
arterialized venous blood. Blood samples
for postabsorptive plasma glucose, insu-
lin, and FFA were performed in triplicate.
Thereafter, a euglycemic-hyperinsuline-
mic clamp was performed as previously
described (13,15). Insulin was infused at
40 mU/[m2  min] to reach a plasma insu-
lin concentration of 450 pmol/l, and
plasma glucose concentration was kept at
5 mmol/l for 150 min by means of a vari-
able infusion of 20% dextrose. Blood sam-
ples for plasma insulin, glucose, and FFA
were collected every 15 min throughout
the study.
Analytical procedures
Plasma glucose was measured with a
Beckman glucose analyzer (Beckman,
Fullerton, CA) (13,15) and coefficient of
variation (CV) was 1.5  0.1 and 2.5 
0.2% in the fasting and clamp conditions,
respectively. Plasma-free insulin was
measured by means of radioimmunoassay
(Incstar, Stillwater, MN) as previously de-
scribed (3). CV was 8.2 0.9 and 3.1 
0.7% in the fasting and clamp conditions,
respectively. Blood samples for assess-
ment of FFA were collected in prechilled
tubes containing 0.1% EDTA. Tubes were
immediately placed on ice and plasma
was immediately processed by centrifuga-
tion at 4°C. Plasma was then frozen and
stored at –70°C, and determination of
FFA was performed as previously de-
scribed (13,15) within 0–5 working days.
CV was 7.1  1.5 and 12.1  1.5% in
the fasting and clamp conditions,
respectively.
Calculations
The glucose infusion rate (GIR) was mea-
sured in steady-state conditions during
the 120–150 min of the insulin clamp
and expressed as mg/[kg  min]; CV was
2.0  0.2%. Insulin sensitivity (SIclamp)
was calculated as follows: GIR/(I  G),
where I is the increment of plasma insu-
lin concentrations during the 120–150
min of the clamp with respect to the basal
condition, and G is the plasma glucose
concentration during the 120–150 min of
the clamp (16). Homeostasis model as-
sessment provided equations for estimat-
ing insulin resistance (HOMA-IR)
HOMA-IR  G0  I0/22.5 (1)
or insulin sensitivity
HOMA-IS  1/HOMA (2)
where I0 (U/ml) is the fasting insulin
concentration, G0 (mmol/l) is the fasting
glucose concentration, and 22.5 repre-
Table 1—Anthropometric, laboratory, and insulin sensitivity characteristics of the study
groups
KP-Tx patients
(n  22)
Normal subjects
(n  18) P
n (men/women) 15/7 11/7 —
On insulin treatment [n (%)] 5 (23%) — —
Age (years) 39  9 34  8 0.10
Transplant age (months) 56  21 — —
BMI (kg/m2) 22.3  2.7 24.1  4.0 0.11
Fasting glucose (mmol/l) 5.36  1.30 4.96  0.50 0.20
Clamp glucose (mmol/l) 4.98  0.32 4.89  0.21 0.28
Fasting insulin (pmol/l) 92  50 43  25 0.01
Clamp insulin (pmol/l) 509  108 417  118 0.02
 Insulin (pmol/l) 417  96 374  107 0.18
Fasting FFA (mmol/l) 0.593  0.235 0.536  0.202 0.41
GIR (mg/[kg  min]) 4.51  1.71 5.76  1.58 0.02
SIclamp (dl/[min  kg]/(U/ml)  10
4 7.89  4.13 11.21  3.89 0.01
HOMA-IS 0.370  0.175 0.795  0.323 0.001
QUICKI 0.325  0.025 0.365  0.027 0.001
Revised QUICKI 0.359  0.047 0.416  0.055 0.001
Data are means  SD.
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sents a constant applied to correct the
value to unity as previously described
(10). QUICKI was calculated as previ-
ously described (12).
QUICKI  1/[log(I0) 	 log (G0)]
(3)
Incorporation of FFA into QUICKI gener-
ated a revised QUICKI, which was calcu-
lated as follows (13)
revised QUICKI  1/[log(I0) 	 (4)
log(G0) 	 log(FFA0)]
where FFA0 (mmol/l) is the fasting FFA
concentration.
Statistical analysis
All data are presented as a mean  SE.
The steady state was defined as a nonsig-
nificant correlation with time (P  0.05)
of the variable using standard linear re-
gression. Relationship between variables
was assessed by means of simple correla-
tion (r) analysis. Comparisons between
the normal and KP-Tx patients were per-
formed using the two-tailed unpaired
Student’s t test.
RESULTS
Anthropometric and laboratory
characteristics of the study subjects
The anthropometric parameters of study
subjects are summarized in Table 1. The
two study groups were matched for an-
thropometric features. Age, sex, BMI, and
fasting plasma glucose and FFA concen-
trations were not different between
groups. On the contrary, KP-Tx patients
were characterized by marked hyperinsu-
linemia when compared with normal
subjects (P  0.01).
Insulin sensitivity in KP-Tx patients
GIR and SIclamp, HOMA-IS, QUICKI, and
revised QUICKI were all significantly re-
duced in KP-Tx patients when compared
with normal subjects (Table 1). Fasting
plasma glucose was not associated with
GIR (r  
0.31, P  0.17) and SIclamp
(r
0.34, P 0.13), and the same was
observed for fasting plasma insulin (r 

0.42, P  0.07 and r  
0.35, P 
0.11, respectively). On the contrary, fast-
ing plasma FFA concentration was asso-
ciated with both GIR (r  
0.63, P 
0.002) and SIclamp (r  
0.67, P 
0.001). GIR was associated with
HOMA-IS (r 0.43, P 0.05), QUICKI
(r 0.46, P 0.03), and revised QUICKI
(r  0.67, P  0.0002) as well as the
SIclamp (r 0.47, P 0.03 with respect to
HOMA-IS; r  0.47, P  0.03 with re-
spect to QUICKI; and r  0.76, P 
0.0001 with respect to revised QUICKI)
(Fig. 1).
Insulin sensitivity in the normal
healthy subjects
In the normal subjects, GIR and SIclamp
fasting plasma glucose were not associ-
ated with GIR (r  
0.23, P  0.32) or
SIclamp (r
0.09, P 0.69). However,
fasting plasma insulin (r  
0.57, P 
0.01 and r  
0.71, P  0.001 with re-
spect to GIR and SIclamp, respectively) and
fasting plasma FFA (r  
0.76, P 
0.001 and r  
0.60, P  0.01 with re-
spect to GIR and SIclamp, respectively)
were significantly associated with both
GIR and SIclamp. GIR was significantly as-
sociated with HOMA-IS (r  0.55, P 
0.02), QUICKI (r  0.58, P  0.002),
and revised QUICKI (r  0.87, P 
0.0001). When SIclamp was used as
clamp-derived estimate of insulin sensi-
tivity, the same trend was observed (r 
0.69, P  0.001 with respect to HOMA-
IS; r  0.71, P  0.0001 with respect to
QUICKI; and r  0.83, P  0.0001 with
respect to revised QUICKI).
CONCLUSIONS — Th i s s tudy
showed that in KP-Tx recipients, HOMA-
IS, QUICKI, and revised QUICKI may be
used as measures of insulin sensitivity as
assessed with the insulin clamp (Fig. 1),
but the revised QUICKI, incorporating
the fasting plasma FFA levels, consider-
ably improved the association with insu-
lin sensitivity and was more reliable than
the other indexes.
HOMA-IS and QUICKI have been
proposed to predict insulin sensitivity in
classical conditions of insulin resistance.
Whether they may be useful surrogates of
insulin sensitivity in KP-Tx patients has
never been assessed before. The surgical
procedure of KP-Tx usually foresees the
anastomosis of the pancreas to the iliac
vein; the liver, which normally clears on
the first pass 40–60% of the insulin se-
creted by the pancreas, is therefore by-
passed in this procedure, determining in
these patients an overall reduction of in-
sulin clearance (17). In agreement with
this fact, KP-Tx patients studied in this
work showed a significant increment of
fasting plasma insulin levels (Table 1),
and we also observed that the relationship
between clamp-based insulin sensitivity
and fasting plasma insulin, detectable in
the healthy matched control subjects (r

0.71, P 0.005), was lost in the KP-Tx
patients (r
0.35, P 0.11). A differ-
ent situation was observed with respect to
the other variables included in HOMA-IS
and QUICKI; in fact, the relationship with
fasting plasma glucose in KP-Tx patients
was not significant (r  
0.33, P 
0.11), but it was not worse than the rela-
tionship observed in the group of control
subjects (r  0.09, P  0.70), in which
fasting plasma glucose was also less infor-
Figure 1—The relationships between the
SIclamp (x-axis) with HOMA-IS (A), QUICKI
(B), and revised QUICKI (C) in KP-Tx pa-
tients. For HOMA-IS and QUICKI, r 0.47, P
0.03; for revised QUICKI, r 0.76, P 0.0001.
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mative than fasting plasma insulin levels.
These findings may partially explain the
reduced association of SIclamp with
HOMA-IS and QUICKI detected in KP-Tx
patients with respect to the healthy, nor-
mal subjects (Fig. 1) and may suggest that
the reason for this reduced association
mainly resides in a reduced association
with fasting plasma insulin.
These findings, the well-known asso-
ciation of increased plasma FFA concen-
tration with insulin resistance in diabetes
(13,18,19) and hypertension (20,21), our
previous observations of the inverse asso-
ciation of fasting plasma FFA concentra-
tion with insulin sensitivity as assessed
with the insulin clamp (19), and the fact
that revised QUICKI, incorporating the
logarithm and the reciprocal of FFA con-
centration to the insulin-glucose product,
was better than QUICKI in normal indi-
viduals and in subjects with moderate al-
terations of insulin sensitivity (13),
suggest that in KP-Tx patients, additional
metabolic markers of insulin action could
be profitably taken into account to im-
prove its association with insulin sensitiv-
ity. Whether the antilipolytic action of
insulin is impaired or unaffected in KP-Tx
patients is controversial (22,23); never-
theless, the fasting FFA levels were homo-
geneously found to be not different than
in control subjects (23,24). In this study,
fasting plasma FFA concentration in
KP-Tx patients was also found to be com-
parable to that of control subjects, and its
association with the clamp-based index of
insulin sensitivity was significant in the
group of healthy subjects (r  
0.60,
P 0.005) and in the KP-Tx patients (r

0.67, P 0.001). As a consequence, the
incorporation of fasting plasma FFA con-
centration into QUICKI considerably im-
proved the relationship of the revised
QUICKI with SIclamp, especially in KP-Tx
patients (Fig. 1).
Graft failure determines recurrence of
diabetes in a significant subset of pancre-
atic graft recipients (1), but identification
of subjects at risk is difficult and often
delayed. Appropriate prevention and
treatment are not feasible because of the
lack of diagnostic accuracy of available
biochemical parameters and imaging
tools. Our group showed that the only
variable that is able to predict the return
to diabetic state for any cause in KP-Tx
was the mean daily glucose concentration
(25), but the small sample size in which
insulin sensitivity was assessed using the
insulin clamp limited the power of the
statistical inference regarding insulin re-
sistance. In a larger scale study, the use of
these indexes based on fasting data might
clarify the impact of metabolic abnormal-
ities on graft failure.
In conclusion, in KP-Tx patients,
HOMA-IS and QUICKI are reliable mea-
sures of insulin sensitivity. The association
with insulin sensitivity is considerably
improved if FFA concentration is taken
into account (revised QUICKI). Revised
QUICKI may be tested for earlier identi-
fication of metabolic abnormalities in
subjects at risk for deterioration of pan-
creatic graft function and development of
cardiovascular disease and may contrib-
ute to large-scale or epidemiological stud-
ies in these patients. This study represents
a necessary prerequisite, and further
work is needed to ascertain whether in-
cluding the fasting FFA concentration in
QUICKI can be applicable to other mod-
els of-cell function replacement, such as
isolated pancreas transplantation, pan-
creas transplantation with portal anasto-
mosis, and islet transplantation.
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